Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
March 07, 2017 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
February 07, 2017 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...
Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
January 31, 2017 08:00 ET
|
Dimension Therapeutics
Evidence of High-Efficiency Liver Transduction with AAVrh10 Vector Sub-clinical, Asymptomatic Elevations of ALT Observed in 5 of 6 Patients CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- ...
Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency
December 13, 2016 08:00 ET
|
Dimension Therapeutics
On Track to Initiate Phase 1/2 Global, Multi-Center Clinical Trial by Year End 2016 Most Advanced of Five Inherited Metabolic Disease Programs Progressing Towards Clinical Testing CAMBRIDGE, Mass.,...
Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting
December 05, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...
Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
November 29, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...
Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results
November 10, 2016 08:00 ET
|
Dimension Therapeutics
Completed patient dosing in cohort 1 and dosing cohort 2 in ongoing Phase 1/2 trial with DTX101 for hemophilia B; clinical data expected in January 2017 IND filing and initiation of Phase 1/2 study...
Dimension Therapeutics Announces Presentation at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting
November 03, 2016 09:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...
Dimension Therapeutics Announces Presentations Highlighting Advances in AAV Manufacturing at the European Society of Gene and Cell Therapy (ESGCT) Congress
October 18, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...
Dimension Therapeutics Announces Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Congress
October 11, 2016 08:00 ET
|
Dimension Therapeutics
CAMBRIDGE, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...